As biotechs face increasingly tight development timelines, scale-up headaches and, more recently, unpredictable policy fluctuations, one way to stand out as a CDMO partner is picking a specialty an | ...

Among the measures ImmunityBio has implemented are “expanded promotional review protocols,” executive training and external ...

The doctors at fictional Sacred Heart Hospital are in, and so is Insulet’s real-life wearable insulin management system ...

Neurocrine Biosciences, forever a possible M&A target in the biopharma industry, is making a major acquisition itself. | ...

A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

VML Health, a marketing and communications company, has identified the concept's emergence as a trend affecting how ...

After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...

Forget March going out like a lamb. On the M&A landscape, March went out like a lion.  | In a flurry of activity, biopharma ...

The U.S. will impose a 100% tariff on drug imports with some exceptions. Takeda plans to cut 634 jobs in the U.S. as part of ...

For more than a year, the biopharma industry has had to swiftly react to various tariff threats from the Trump administration. | The president has rolled out a 100% tariff rate on patented ...

The U.K. can officially declare itself free of tariffs on drug exports to the U.S. after its government signed off on the ...

On the heels of a comprehensive review, BioNTech has decided “to close its planned Singapore site by the end of February 2027 ...